Dr. Reddy's Launches Ephedrine Sulfate Injection USP, 50 mg/mL, Single-Dose Vial in the US Market
29 October 2021 - - Indian pharmaceutical company Dr. Reddy's Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) (NSEIFSC: DRREDDY) has launched in the US market Ephedrine Sulfate Injection USP, 50 mg/mL, a therapeutic equivalent generic version of Akovaz (ephedrine sulfate injection) Injection, 50 mg/mL approved by the US Food and Drug Administration (USFDA), the company said.

The Akovaz brand and generic market had US sales of approximately USD 67.5m MAT for the most recent twelve months ending in August 2021 according to IQVIA Health.

Dr. Reddy's Ephedrine Sulfate Injection USP, 50 mg/mL is a clear, colorless, sterile solution for intravenous injection and supplied as a 1 mL fill in a 2 mL clear glass single-dose vial with purple flip-off cap. Each mL contains 50 mg of ephedrine sulfate USP, equivalent to 38 mg ephedrine base.